Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Concord Drugs Ltd

Your Vote -

Buy

86.67%

Hold

0.00%

Sell

13.33%

86.67%

15 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Concord Drugs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Concord Drugs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    15 Apr 2025, 4:36PM Certificate under Reg 74(5) of SEBI(DP) Regulations, 2018.
  • Concord Drugs has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    15 Apr 2025, 7:00AM As of March 2025, 54.39% is owned by Indian Promoters and 45.61% by Public. <p align=justify> Top three Promoters holding highest number of shares of
  • Concord Drugs - Board Meeting Outcome for Outcome Of Board Meeting

    17 Mar 2025, 6:18PM Outcome of Board Meeting
  • Concord Drugs - Board Meeting Intimation for Reschedule Of Board Meeting

    13 Mar 2025, 5:25PM Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/03/2025 ,inter alia, to consider and ap
  • Concord Drugs - Board Meeting Intimation for To Consider Fund Raising By Way Of Preferential Issue

    4 Mar 2025, 4:50PM Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/03/2025 ,inter alia, to consider and ap

Key fundamentals

Evaluate the intrinsic value of Concord Drugs Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 47.8258 46.5061 44.7948 39.7395 33.0529
Liabilities 47.8258 46.5061 44.7948 39.7395 33.0529
Equity 10 9.3155 8.7437 8.7438 8.7438
Gross Profit 3.6772 4.3437 5.5924 3.2198 3.344
Net Profit 0.4194 0.8922 1.5943 3.2817 0.3283
Cash From Operating Activities 1.9598 2.2448 0.7741 1.6157 2.1555
NPM(%) 0.96 1.73 2.7 6.38 0.63
Revenue 43.2607 51.3143 58.9564 51.357 51.3389
Expenses 39.5835 46.9706 53.3639 48.1372 47.9949
ROE(%) 1.23 2.63 4.7 9.68 0.96

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Concord Drugs Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 824.20 -1.99 11.65 17.09 1321.50 1.39
Lotus Eye Hospital and Institute Ltd 80.41 -0.74 338.42 62.28 14.01 0.62
Bharat Immunological and Biologicals Corporation Ltd 23.00 -1.41 0.00 129.32 -39.50 0.00
Astec Lifesciences Ltd 681.00 -1.58 0.00 58.73 -687.11 0.00

Company Info

Concord Drugs Limited (CDL) is incorporated as a Limited Company on 24th April 1995 with the Registrar of companies, Andhra Pradesh. The registered office of the Company is situated at Survey No. 249, Brahmanpally Village, Hayatnagar Mandal, R.R. District, Hyderabad-501511 Concord Drugs Limited was established in 1995 to manufacture and market innovative pharmaceutical products. Concord's three core product areas are generics, branded and specialty pharmaceuticals. The Company ranks among the top generics suppliers in India. Manufacturers of AMCRYLATE [ISO Amyl 2-Cyanoacrylate] a sterile tissue adhesive used in for sutureless surgeries first time in Asia in collaboration with Indian Institute of Chemical Technology [IICT], Hyderabad a premier CSIR Laboratory. The Technology Information, Forecasting and Assessment Council [TIFAC], New Delhi has helped the company to mass produce `AMCRYLATE' and bring it to Indian consumers. TIFAC was also associated in providing Techno-managerial guidance to the Company. The product is patented in India for Concord Drugs Limited. Further the Company has established Unit-II or Phase-II at Roorkee, Uttrakhand in 2005 for manufacturing of Tablets & Capsules.AMCRYLATE is non-pigmented, non-toxic, non-allergic, bacteriostatic and bio-static adhesive. It allows rapid wound closure with minimal scarring, reduces the risk of post surgical infection and trauma, besides being simple and safe to use.Also set-up a plant for Small Volume Parenterals in liquid ampoules/vials and powder Parenterals and also Tablets & Capsules with Betalactum & Non-Betalactum both sections. 2015 -Concord Drugs Ltd are listed and admitted to dealings on the Exchange in the list of 'DT' Group Securities.

Concord Drugs Limited (CDL) is incorporated as a Limited Company on 24th April 1995 with the Registrar of companies, Andhra Pradesh. The registered office of the Company is situated at Survey No. 249, Brahmanpally Village, Hayatnagar Mandal, R.R. District, Hyderabad-501511 Concord Drugs Limited was established in 1995 to manufacture and market innovative pharmaceutical products. Concord's three core product areas are generics, branded and specialty pharmaceuticals. The Company ranks among the top generics suppliers in India. Manufacturers of AMCRYLATE [ISO Amyl 2-Cyanoacrylate] a sterile tissue adhesive used in for sutureless surgeries first time in Asia in collaboration with Indian Institute of Chemical Technology [IICT], Hyderabad a premier CSIR Laboratory. The Technology Information, Forecasting and Assessment Council [TIFAC], New Delhi has helped the company to mass produce `AMCRYLATE' and bring it to Indian consumers. TIFAC was also associated in providing Techno-managerial guidance to the Company. The product is patented in India for Concord Drugs Limited. Further the Company has established Unit-II or Phase-II at Roorkee, Uttrakhand in 2005 for manufacturing of Tablets & Capsules.AMCRYLATE is non-pigmented, non-toxic, non-allergic, bacteriostatic and bio-static adhesive. It allows rapid wound closure with minimal scarring, reduces the risk of post surgical infection and trauma, besides being simple and safe to use.Also set-up a plant for Small Volume Parenterals in liquid ampoules/vials and powder Parenterals and also Tablets & Capsules with Betalactum & Non-Betalactum both sections. 2015 -Concord Drugs Ltd are listed and admitted to dealings on the Exchange in the list of 'DT' Group Securities.

Read More

Parent Organisation

Concord Drugs Ltd.

Founded

24/04/1995

Managing Director

Mr.S Nagi Reddy

NSE Symbol

FAQ

The current price of Concord Drugs Ltd is

The 52-week high for Concord Drugs Ltd is

The market capitalization of Concord Drugs Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Concord Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Concord Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Concord Drugs Ltd shares.

The CEO of Concord Drugs Ltd is Mr.S Nagi Reddy, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT